Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on Arcus Biosciences (NYSE: RCUS).The analyst commented, "Following Merck’s failed Phase ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments